PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143390
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143390
qPCR Instruments market size was valued at US$ 1,301.9 Million in 2025, expanding at a CAGR of 7.3% from 2026 to 2033.
The qPCR Instruments market refers to the market of the benchtop and high-throughput real-time PCR instruments that work by the principle of the fluorescence intensity change during the nucleic acid target DNA sequences amplification process. The core components of a qPCR instrument include a very accurate thermal cycler with the heating/cooling system, a light source with the excitation/emission filter, and a highly sensitive detector such as CMOS or PMT that measures the fluorescence intensity of each well in real time. Software solutions are available to automatically correct the baseline, calibrate the efficiency, and make the comparative analysis of the results. The technology is highly flexible and may be used in many spheres, including clinical diagnostics, drug development, biological research, etc. These integrated technologies enable precise, rapid, and reliable nucleic acid quantification across diverse applications.
qPCR Instruments Market- Market Dynamics
Rising Prevalence of Respiratory Viruses to Drive Market Growth
The rising prevalence of respiratory viruses is driving the qPCR Instruments market. Because of the continued emergence of respiratory viruses such as influenza, RSV, SARS-CoV-2, and human metapneumovirus and other respiratory ailments, there is an anticipated increase in demand for rapid and accurate molecular tests, leading to an increase in the utilization of qPCR instruments for molecular diagnostics, surveillance, and pathogen identification. For instance, in August 2026, according to the UK Health Security Agency (Gov.), the positivity rate of respiratory syncytial virus (RSV) for people that took PCR tests in England increased from 7.22 percent in the week that started on 5 January 2026 to 0.21 percent in the week that started on 3 August 2026, respectively. Based on the dashboard, the positivity rate of RSV increased to 10.86 percent of people tested during the weeks that started from December 1, 2025, to January 26, 2026. The positivity rate of RSV was 6.60 percent on January 12, 2026; 5.99 percent on January 19, 2026; and 4.86 percent on January 26, 2026. This seasonal rise in respiratory infections is strengthening demand for qPCR-based molecular testing solutions.
The Global qPCR Instruments market is segmented on the basis of Instrument, Type, Application, End User, and Region.
Based on instruments, QuantStudio holds a major share in the qPCR Instruments market because of its wide applications in clinics and research, sensitivity and reproducibility, large number of different assays, and the market requirements for the accuracy and high-throughput real-time qPCR instruments.
In July 2025, Thermo Fisher Scientific increased their portfolio of real-time qPCR instruments, QuantStudio real-time PCR. They have upgraded their qPCR technique, instrument, and software used for research and development of diagnostics research and molecular biology research applications. This has upgraded their capacity and effectiveness in using the QuantStudio systems. Increased capacity and effectiveness of the QuantStudio systems have made it possible to make an accurate and high-throughput quantification of the nucleic acid, hence improving overall efficiency of the laboratory and increasing the application scope of qPCR in research and clinics.
qPCR Instruments Market- Geographical Insights
North America held a prominent position in the qPCR Instruments market due to increasing demands for speedy and accurate molecular diagnostics. The use of qPCR for diagnosing diseases linked with respiratory conditions, pandemics, and population health surveillance in North America is increasing. For example, according to the Government of Canada's Health of People in Canada Dashboard, in June 2026, population health surveillance will be established by means of over 50 interactive health indicators (population health of people in Canada). The HPC dashboard enables an easy way of presenting data in relation to topics, selected indicator data and its summary, trends, etc. Population health information has been presented by working together with Health Canada, the Public Health Agency of Canada, the Canada Mortgage and Housing Corporation, and Employment and Social Development Canada, among others who have provided data and expertise. This expanding surveillance infrastructure is expected to support greater adoption of qPCR technologies across North America.
Europe's qPCR Instruments market is growing steadily, which means that there have been increased investments in high-throughput molecular diagnostics, public health surveillance, and modern laboratory testing. Faster outbreak preparedness and disease detections have been among the critical factors contributing to the growth of this market. For instance, in April 2026, according to the World Health Organization (WHO), 27 out of the 28 EU Member States surveyed on artificial intelligence in healthcare showed that in the period between March 2025, 74% of the EU member states were already using AI in disease diagnosis through disease detection, medical imaging, and treatment decision-making, implying that there has been widespread use of AI technology for disease detection in Europe, while 63% were using AI chatbots in patient engagement, and 81% of the EU member states were involving stakeholders in the governance of AI in health. These trends are accelerating adoption of advanced qPCR technologies for faster, data-driven disease detection.
The qPCR Instruments market features prominent companies including Thermo Fisher Scientific, F. Hoffmann-La Roche, Bio-Rad Laboratories, Danaher, and QIAGEN. The companies are using various merger, acquisition, and alliance strategies to gain access to advanced technology to develop innovative solutions for entering into new markets. In March 2025, Roche launched a novel LightCycler PRO System in 7 global markets, which is the next generation of qPCR systems, which can help fulfill research laboratory and clinical diagnostic processes, with an immense impact on dual-mode capabilities, 7-channel amplification, homogeneous temperature control, and advanced data analysis. The developments have increased the level of competition in the qPCR instruments market.
In June 2026, QIAGEN introduced further assays, multiplexing, automation, and data analysis tools that were expected to improve the application of digital PCR in research and development as well as biopharmaceutical applications within their QIAcuity gene-expression product portfolio.
In February 2025, Bio-Rad presented Stilla Technologies with a binding deal to acquire the company, which develops instruments, consumables, and assays in connection with digital PCR technology and to accelerate development of next-generation PCR solutions.